A communication from the Executive Office of Health and Human Services (see item 4000-0300 of Section 2 of Chapter 9 of the Acts of 2025) submitting a report on MassHealth pharmaceutical spending and utilization for fiscal year 2025

This document is a report submitted by the Executive Office of Health and Human Services detailing MassHealth pharmaceutical spending and utilization for fiscal year 2025, as required by a 2025 state law. The report outlines that the state spent approximately $3.01 billion on drugs in FY25 before rebates, while collecting about $1.69 billion in rebates through direct negotiations with drug manufacturers. It also projects that spending will rise to $3.36 billion in FY26 due to increased use of high-cost medications, with an estimated rebate collection of $1.75 billion. The report confirms that these negotiation efforts have not restricted patient access to FDA-approved drugs and notes that new drugs added to the state formulary have had a minimal financial impact to date.